Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENA maintenance study in frontline ovarian cancer
2024-516662-11-00Phase 3Completed
- Sponsor
- pharma&
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of rucaparib and nivolumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 arms), sponsored by pharma&. Primary endpoint: Investigator-determined progression-free survival. Started Nov 2024; status: completed.
02
Drugs
rucaparibnivolumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-516662-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516662-11-00.